Davis Polk advised Auris Medical Holding AG in connection with the SEC-registered offering of $1.5 million of its common shares to Lincoln Park Capital Fund, LLC. The common shares are listed on the NASDAQ Capital Market under the symbol “EARS.” In addition, Davis Polk advised Auris Medical in connection with the establishment of an equity line of financing, pursuant to which Lincoln Park Capital has agreed to purchase up to $13.5 million of Auris Medical’s common shares from time to time. The price of the common shares will be based on the prevailing market prices of Auris Medical’s common shares at the time of each issuance to Lincoln Park Capital.
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in neurotology.
The Davis Polk capital markets team included partner Sophia Hudson and associates Pedro J. Bermeo, Eugene Baek and Jaryn S. Fields. The tax team included partners Kathleen L. Ferrell and William A. Curran and associate Andrew Imber. Associate Brantley Hawkins provided 1940 Act advice. All members of the Davis Polk team are based in the New York office.